Advances in drug development: Next generation clinical trials

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 8, 2011, Pages 601-603

  Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MEDICAL LITERATURE; MEDICAL RESEARCH; PROCESS DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; STUDY DESIGN; TREATMENT FAILURE; DRUG DEVELOPMENT; HUMAN; INTERVIEW; METHODOLOGY; NEOPLASM; STANDARD;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 80053082863     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Biswasa P, Liub D, Leeb JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials. 2009; 6:205-216.
2. title typecontributorBreast Cancer I-SPY 2 Trial/title. http://ispy2.org/about.
3. Johnson V, Cook J. Bayesian design of single-arm phase II clinical trials with continuous monitoring. Clin Trials. 2009;6:217-226.